Atossa Therapeutics Set to Release Earnings on March 25

Atossa Therapeutics (NASDAQ:ATOS) is scheduled to release its quarterly earnings on Tuesday, March 25th. Analysts predict that the company will report earnings of ($0.06) per share for the quarter.

Atossa Therapeutics has seen some fluctuations in its stock price, which opened at $0.72 on Friday. The company boasts a market capitalization of $90.01 million, a negative price-to-earnings ratio of -3.25, and a beta of 1.20. Its 50-day moving average stands at $0.81, while the 200-day moving average is $1.13. Over the past year, Atossa's stock has reached a low of $0.66 and a high of $2.31.

Institutional Investor Involvement

Recently, an institutional investor has increased its stake in Atossa Therapeutics. Bank of America Corp DE raised its position in the company by 51.3% during the fourth quarter, according to their latest SEC filing. Following this acquisition, they owned 111,475 shares, valued at around $105,000 at the end of the last reporting period. Overall, institutional investors and hedge funds hold about 12.74% of Atossa Therapeutics' stock.

Analyst Opinions

Several equity analysts have commented on Atossa Therapeutics recently. HC Wainwright reaffirmed a "buy" rating and set a target price of $7.00 for the company's shares in a report dated March 12th. Additionally, Ascendiant Capital Markets raised their target price from $6.50 to $7.00 with a "buy" rating noted in a report from December.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for unmet medical needs in oncology, particularly in women's breast cancer. Its lead drug candidate, oral (Z)-endoxifen, is currently undergoing Phase II clinical trials aimed at both treating and preventing breast cancer.

Investment Considerations

Before investing in Atossa Therapeutics, it's prudent to note that while it holds a Buy rating among analysts, there are other stocks that some top-rated analysts recommend as better investment opportunities.

Atossa, Earnings, Stocks